Semaglutide & Tirzepatide: Insurance Coverage and Prior Authorization
FDA approval is a regulatory fact. Coverage is a separate business decision made by each payer. Understanding the gap between the two is the most useful thing you can do before committing to a treatment path.
Updated: April 2026 · 5 official sources
FDA Approval Does Not Equal Coverage
The FDA approves a drug for a specific indication based on safety and efficacy data. That approval authorizes prescribing — it does not obligate any payer to cover the cost. Insurers, Medicare Part D plans, Medicaid programs, and employer-sponsored plans each set their own formulary and coverage criteria independently.
A drug being FDA-approved means a licensed physician can legally prescribe it in the US. It says nothing about whether your specific plan will pay for it, at what tier, under what conditions, or at all.
- •Drug meets safety and efficacy standards
- •Licensed prescribers can write a prescription
- •Drug can be legally dispensed at pharmacies
- •Official label defines approved indications
- •Your insurance will cover it
- •You will pay anything less than list price
- •Prior authorization will be approved
- •Your plan places it on a favorable formulary tier
Obesity vs Diabetes: The Coverage Split
Semaglutide and tirzepatide each have multiple branded products with different indications. The coverage behavior for an obesity indication and a diabetes indication can differ dramatically — even when the active molecule is the same.
Commercial plans vary widely. Many require prior auth and BMI or comorbidity documentation. Medicare Part D historically excluded anti-obesity drugs; CMS coverage expansions are ongoing and plan-specific.
Diabetes-indication coverage is generally broader. Commercial plans and Medicare Part D typically cover diabetes medications, though tier placement and copay vary by plan.
Same commercial coverage variability as Wegovy. Eli Lilly official savings and self-pay vial programs exist for those without coverage.
This page describes general coverage patterns. Your actual plan benefit, formulary tier, prior authorization criteria, and step-therapy requirements will be plan-specific. Always confirm current benefits with your insurer or a provider who can run benefit verification.
What Prior Authorization Actually Involves
Prior authorization (PA) is a process where your insurer requires your prescriber to get approval before the plan will cover a specific drug. It is not a reflection of medical necessity — it is a cost-control mechanism. For obesity-indication GLP-1 medications, PA requirements are common.
Your doctor submits clinical documentation to your insurer — typically including diagnosis codes, BMI, comorbidity evidence, and sometimes prior treatment history.
Each plan has internal criteria. Common requirements include BMI thresholds, comorbidity documentation (hypertension, diabetes, sleep apnea), and sometimes a step-therapy requirement (failing a prior intervention).
The plan approves, denies, or requests a peer-to-peer review between your doctor and the plan's medical director. Denials can be appealed.
Approvals are typically time-limited (often 12 months). Renewal often requires documentation of treatment response and adherence.
Some telehealth and direct-care providers specialize in navigating PA for GLP-1 medications and have established workflows with common payers. Choosing a provider with that experience can meaningfully reduce the time and friction involved.
Official Savings Options When Coverage Falls Short
When insurance does not cover or partially covers these medications, manufacturer savings programs are the primary legitimate path to reducing out-of-pocket cost. These are the official sources — not third-party coupons or gray-market channels.
Official savings program for eligible commercially insured and uninsured patients. Eligibility and terms are program-specific and subject to change.
Official program page →For commercially insured patients. Terms and eligibility vary. Not valid for government-program beneficiaries (Medicare, Medicaid).
Official program page →Eli Lilly also offers a self-pay vial option for Zepbound for patients who choose to pay out of pocket without insurance involvement. Check official terms.
Official program page →For the tirzepatide diabetes-indication brand. Eligibility and program terms vary by insurance status and state.
Official program page →Manufacturer savings cards are typically not valid for Medicare or Medicaid beneficiaries. CMS coverage policy for anti-obesity medications continues to evolve — check your plan's current formulary or speak with your provider for current status.
What to Ask Before Starting a Provider Path
The right questions reduce wasted time and help you find a prescribing workflow that actually fits your insurance situation, budget, and urgency.
- ›Does my plan cover Wegovy / Zepbound for obesity?
- ›Is prior authorization required?
- ›What documentation does the PA criteria require?
- ›What is the formulary tier and expected copay if covered?
- ›Do you handle prior authorization for GLP-1 medications?
- ›Do you run benefit verification before the first appointment?
- ›What is your workflow if PA is denied?
- ›Do you offer a self-pay or cash-pay path if coverage falls through?
- ›What is the realistic out-of-pocket cost if not covered?
- ›Which official savings programs do you help patients access?
- ›Is the Zepbound self-pay vial option available through your practice?
- ›Are there lower-cost formulations or dose adjustments that improve affordability?
- ›Which indication and brand fits my clinical situation?
- ›Is telehealth intake available and does that affect my coverage?
- ›What is the follow-up cadence and what does it cost?
- ›How do you handle prior auth renewals?
Finding a Provider Who Can Navigate This
Coverage friction is real, but it is not equally difficult with every provider. Some practices run benefit verification before the first appointment, have established PA workflows, and know which payers approve at what thresholds. Use the provider matcher to compare paths by state, insurance posture, budget, intake mode, and treatment fit before you choose.
Find a provider who handles prior authorization
Compare treatment paths by state, insurance, budget, and intake mode. Use the matcher before committing to a prescribing workflow.
Use provider matcherSemaglutide and tirzepatide pricing, savings, and cash-pay reality.
Open →Approved products, routes, provider path, and tracker next steps.
Open →Approved products, routes, provider path, and tracker next steps.
Open →Sources
- 1. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight LossFDAClaim type: regulatoryView source →
- 2. Wegovy Savings Card and Patient SupportWegovyClaim type: pricingView source →
- 3. Ozempic Savings Offer and Patient SupportOzempicClaim type: pricingView source →
- 4. Zepbound Savings and SupportZepboundClaim type: pricingView source →
- 5. Medicare Part D Coverage of Anti-Obesity Medications — Policy ClarificationCMSClaim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.